Effectiveness and safety of oral HIV preexposure prophylaxis for all populations.
Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O'Reilly KR, Koechlin FM, Rodolph M, Hodges-Mameletzis I, Grant RM. · 2016
Read Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. by Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O'Reilly KR, Koechlin FM, Rodolph M, Hodges-Mameletzis I, Grant RM. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4949005.txt.
Description
Virginia A. Fonner and eight co-authors pool the evidence on oral preexposure prophylaxis, or PrEP, against HIV. Their systematic review and meta-analysis appeared in AIDS in 2016. PrEP means taking a daily pill with the drug tenofovir before exposure, to block infection. The team searched databases and conference reports through April 2015 for trials and studies of safety, resistance, behavior, and pregnancy outcomes.
Eighteen studies qualified. Across groups and dosing plans, PrEP cut the risk of HIV infection versus placebo. Trials where use topped seventy percent showed the strongest effect. Trials with low use showed no clear benefit. Side effects matched placebo rates, and there was no sign that users took more sexual risks. The authors conclude PrEP works when taken, and they call for best practices that help people start and stay on it.
Catalog record
| CREATOR | Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O'Reilly KR, Koechlin FM, Rodolph M, Hodges-Mameletzis I, Grant RM. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |